Heparin News and Research

RSS

Heparin, a highly-sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. It can also be used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machines. Pharmaceutical grade heparin is derived from mucosal tissues of slaughtered meat animals such as porcine (pig) intestine or bovine (cow) lung.

New study details trends in diagnosis, treatment of brain tumours

A two year study involving over 560 patients with the newly-diagnosed malignant brain tumors shows that patterns of care are varied and there is a need for new, detailed clinical guidelines for management of brain tumors. The study is published in the Feb. 2, 2005 issue of the Journal of the American Medical Association (JAMA).

3 Feb 2005

Drug reviparin reduces the risk of death after heart attack

The drug reviparin (a low molecular weight heparin anticoagulant), when administered to patients with a heart attack, is effective in reducing the risk of death and the risk of a subsequent heart attack, according to a study in the January 26 issue of JAMA.

26 Jan 2005

New insight into anticoagulation therapies

Anticoagulation therapies, or treatments that reduce the amount of clotting factors in the blood, are quite common and used for a variety of reasons.

6 Dec 2004

Reviparin significantly reduces death and repeat heart attacks without increasing the risk of stroke

A major Canadian-led global study has found that an inexpensive anti-blood-clotting drug significantly reduces death and repeat heart attacks without increasing the risk of stroke.

8 Nov 2004

Researchers have developed a novel drug-antidote pair

In a discovery that could give physicians more control over the actions of medications, researchers at Duke University Medical Center have developed a novel drug pair – a potent anti-coagulant with a matched "antidote."

18 Oct 2004

Researchers discover mechanism that may help to explain how angiogenesis inhibitors work on normal, blood vessel-forming endothelial cells

Northwestern University researchers have discovered a mechanism that may help to explain how angiogenesis inhibitors work on normal, blood vessel-forming endothelial cells, but not on insidious, aggressive melanoma cells that masquerade as endothelial-like cells by forming their own vascular networks, called "vasculogenic mimicry."

8 Oct 2004

Guidelines introduce novel therapies for the prevention and treatment of thrombosis

New antithrombotic guidelines from the American College of Chest Physicians (ACCP) introduce novel therapies for the prevention and treatment of thrombosis and, for the first time, offer specific recommendations for long-distance travelers.

14 Sep 2004

Half of the complications and deaths due to in-hospital DVT can be prevented with once daily dalteparin

Current research supports the use of blood-thinners to help acutely ill, hospitalized patients minimize the risk of death from a pulmonary embolism (PE) and its precursor deep vein thrombosis (DVT).

3 Aug 2004

Anticoagulant therapy with enoxaparin is an effective alternative to heparin therapy for patients with acute coronary syndromes

Two new major studies suggest that anticoagulant therapy with enoxaparin is an effective alternative to heparin therapy for patients with acute coronary syndromes (ACS)

7 Jul 2004

Anti-clotting treatment underused at many hospitals

Academic hospitals are more likely than community or Veteran’s Administration (VA) hospitals to follow national guidelines for treating patients at risk for blood clots with aspirin or warfarin.

19 May 2004

New and Generic Drug Approvals from FDA

Colgate Total Toothpaste, Heparin Sodium in 5% Dextrose Injection, Heparin Sodium in 0.9% Sodium Chloride Injection and others

14 Apr 2004

GlaxoSmithKline acquires injectable anti-thrombotic agents Fraxiparine® and Arixtra®

GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.

13 Apr 2004

Forward step in treatment of Allergic Rhinitis

Rigel Pharmaceuticals, Inc. has announced the presentation of clinical data for R112, the company’s lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.

22 Mar 2004